20/20 BIOLABS, INC. (AIDX) Operating Margin
- Operating margin · 12 months: Value -215.69%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -215.69% | Operating income / revenue. Period ending 2026-06-30. $-4.40M ÷ $2.04M × 100 ≈ -215.69% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -4.40M USD | Operating Income (Loss) |
| Revenue | 2.04M USD | |
| Cost of products and services | (m) | |
| Research and development | 672.73K USD | Research and Development Expense |
| Selling, general and administration | 4.37M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-4.40M | $2.04M | (m) | $672.73K | $4.37M | -215.69% |
| 2026-03-31 | $-4.00M | $1.84M | (m) | $609.22K | $3.89M | -216.95% |
| 2025-12-31 | $-3.33M | $2.05M | (m) | $592.57K | $3.34M | -162.87% |
| 2025-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $-5.68M | $1.75M | (m) | $1.26M | $4.76M | -323.99% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGENOMICS INC (NEO) | United States | $2.514B | -35.96 |